Relationship between adiponectin and copeptin levels with long-term cardiovascular mortality in ST-segment elevation myocardial infarction after percutaneous coronary intervention.

OBJECTIVE: The aim of this study was to determine adiponectin and copeptin levels that might be prognostic for cardiovascular mortality (CvsM) in ST-segment elevation myocardial infarction (STEMI) patients who had percutaneous coronary intervention (PCI). METHODS: Patients who underwent PCI between November 2010 and April 2011 were enrolled and followed for more than eight years. The baseline, demographic and angiographic findings, in-hospital follow up, laboratory results including adiponectin and copeptin levels, and echocardiographic data of the patients were evaluated. RESULTS: There were 78 males and 20 females. The CvsM rate was 26.66% at 112 months of follow up. Some factors were significantly related to CvsM and adiponectin level was an independent predictor of mortality. A cut-off value of ≥ 8 950 ng/ml for adiponectin and ≥ 7.41 ng/ml for copeptin was related to a 3.01- and 2.83-times higher CvsM risk, respectively. CONCLUSION: Adiponectin level was a predictor for CvsM. Higher levels of adiponectin and copeptin could predict a higher risk of CvsM in STEMI patients.

Evaluation of Asymmetric Dimethylarginine Levels in Patients With Chronic Thromboembolic Pulmonary Hypertension Undergoing Pulmonary Endarterectomy.

BACKGROUND: Chronic thromboembolic pulmonary hypertension (CTEPH) is a form of pulmonary embolism, and pulmonary endarterectomy (PEA) is the surgical treatment. Asymmetric dimethylarginine (ADMA) levels are increased in pulmonary hypertension. This study aimed to investigate serum ADMA levels in patients with CTEPH, the effect of PEA on ADMA, and its prognostic value in long-term mortality. METHOD: Eighty (80) patients with CTEPH and 32 healthy controls were included. Preoperative serum ADMA levels, determined using an enzyme-linked immunosorbent assay, were compared between patients with CTEPH and controls. Of 80 patients, 64 had PEA. Pre- and 6-month postoperative serum ADMA levels, 6-minute walk distance (6MWD), and haemodynamic parameters were collected from patients undergoing PEA. Patients were followed-up for survival analysis. RESULTS: Mean ± standard deviation serum ADMA levels were significantly higher in patients with CTEPH compared with controls (0.79±0.32 µmol/L vs 0.52±0.12 µmol/L; p=0.0001). Statistically significant differences were observed between preoperative and postoperative serum ADMA levels (0.78±0.30 µmol/L vs 0.62±0.22 µmol/L; p=0.0001), 6MWD (p=0.0001), and pulmonary vascular resistance (p=0.0001) in 60 patients who underwent and survived PEA. The decrease in serum ADMA levels and increase in 6MWD were significantly correlated (r=-0.286, p=0.027). No other correlation was found. Perioperative mortality was 6.3%, and the survival rate with a mean follow-up of 34.57±8.20 months was 93.3%. Patients with serum ADMA levels >0.8 µmol/L had a significantly lower survival rate (logrank: 5.86; p=0.015). CONCLUSIONS: Levels of circulating ADMA might add diagnostic and prognostic information in CTEPH. Pulmonary endarterectomy is associated with an improvement in serum ADMA levels. Preoperative serum ADMA levels may be useful for estimating the outcome of PEA.

Association between left ventricular dysfunction, anemia, and chronic renal failure. Analysis of the Heart Failure Prevalence and Predictors in Turkey (HAPPY) cohort.

BACKGROUND: Anemia and chronic renal failure (CRF) are frequent comorbidities in patients with heart failure (HF), and they have been reported to be associated with increased mortality and hospitalization rates. HF, anemia, and CRF have been reported to interact with each other forming a vicious cycle termed cardio-renal-anemia syndrome. The aim of the present study was to evaluate the association of HF, anemia, and CRF using data from the large-scale"Heart Failure Prevalence and Predictors in Turkey (HAPPY)" study. PATIENTS AND METHODS: Among the HAPPY cohort, 3,369 subjects who had either left ventricular dysfunction (LVD) or normal left ventricular function on echocardiography or normal serum NT-proBNP levels were included in this analysis. RESULTS: The prevalence of anemia and CRF was significantly higher in patients with LVD compared with subjects with normal ventricular function (20.7 % vs. 4.0 % and 19.0 % vs. 3.7 %, respectively; p < 0.001 for each). Binary logistic regression analyses for the presence of LVD, anemia, and CRF demonstrated that each one was an independent predictor for the presence of the others. CONCLUSION: These findings point to the presence of cardio-renal-anemia syndrome and the necessity of treating these comorbidities in patients with HF.

Drug-eluting stents: from randomized trials to the real world.

Drug-eluting stents have been developed to prevent in-stent restenosis following percutaneous coronary revascularization. In a number of randomized trials, polymer-coated sirolimus- and paclitaxel-eluting stents have been proven to markedly reduce the incidence of angiographic restenosis and repeat revascularization when compared to bare metal stents. Effectiveness of sirolimus-eluting stents in the prevention of restenosis has been confirmed in many subsets of patients and lesions not included in randomized trials, such as in-stent restenosis, chronic total occlusion, acute myocardial infarction, and others. Very promising data in the real world are emerging for utilization of paclitaxel-eluting stents as well. Other drug-eluting stents gave less brilliant results or even true failures, whilst a number of new drugs and stent platforms are under clinical or preclinical evaluation. In this review we describe the main clinical trials on drug-eluting stents, and the most recent informations derived from observational studies and registries. Moreover, preliminary results on new drug-eluting stents are summarized.

Routine sirolimus eluting stent implantation for unselected in-stent restenosis: insights from the rapamycin eluting stent evaluated at Rotterdam Cardiology Hospital (RESEARCH) registry.

OBJECTIVE: To assess the effectiveness of routine sirolimus eluting stent (SES) implantation for unselected patients with in-stent restenosis and to provide preliminary information about the angiographic outcome for lesion subgroups and for different in-stent restenosis patterns. DESIGN: Prospective, single centre registry. SETTING: Tertiary referral centre. PATIENTS: 44 consecutive patients (53 lesions) without previous brachytherapy who were treated with SES for in-stent restenosis were evaluated. Routine angiographic follow up was obtained at six months and the incidence of major adverse cardiovascular events was evaluated. RESULTS: At baseline, 42% of the lesions were focal, 21% diffuse, 26% proliferative, and 11% total occlusions. Small vessel size (reference diameter < or = 2.5 mm) was present in 49%, long lesions (> 20 mm) in 30%, treatment of bypass grafts in 13%, and bifurcation stenting in 18%. At follow up, post-SES restenosis was observed in 14.6%. No restenosis was observed in focal lesions. For more complex lesions, restenosis rates ranged from 20-25%. At the one year follow up, the incidence of death was 0, myocardial infarction 4.7% (n = 2), and target lesion revascularisation 16.3% (n = 7). The target lesion was revascularised because of restenosis in 11.6% (n = 5). CONCLUSIONS: Routine SES implantation is highly effective for focal in-stent restenosis and appears to be a promising strategy for more complex patterns of restenosis.

Sirolimus-eluting stents for the treatment of in-stent restenosis.

The treatment of in-stent restenosis (ISR) remains one of the major therapeutic challenge for the interventional cardiologist. All percutaneous mechanical approaches have shown disappointing results and the recurrence of ISR was reported to be unacceptably high. Currently, the only proven effective therapy available for the treatment of ISR, at least for the most complex lesions, is vascular brachytherapy. However, this therapy is limited by potential side effects and logistic requirements. The introduction of drug-eluting stents, that carry and release antiproliferative agents, have demonstrated to virtually eliminate ISR in de novo lesions. In the light of this promising results for de novo lesions, sirolimus-eluting stents (SES) were recently used for the treatment of ISR in 2 pilot studies. In Sao Paulo, 25 patients with ISR treated with SES (1.4 stent per lesion) presented 4% ISR and no clinical events at 1 year. In Rotterdam, 16 patients with severe ISR were treated with 26 SES. Intravascular ultrasound evaluation demonstrated successful inhibition of neointimal hyperplasia with 1.1% volume obstruction of the stent, which is similar to the Sao Paulo series (0.8%). At 9 months clinical follow-up, 3 patients had experienced 4 major adverse cardiac events (2 deaths and 1 acute myocardial infarction necessitating repeat target vessel angioplasty). With the results presently available, SES implantation can be considered safe and potentially efficacious in the treatment of ISR. However, multicenter, long-term randomized studies are warranted in order to evaluate this new treatment concept.

Which method should be used to determine the obesity, in patients with coronary artery disease? (body mass index, waist circumference or waist-hip ratio).

OBJECTIVE: To determine body mass index (BMI), waist circumference and waist-hip ratio (WHR) in cases with angiographically established coronary artery disease (CAD) and to compare the obesity degrees established according to the ranges determined by the International Guidelines Committees for BMI, waist circumference and WHR. DESIGN: Cross-sectional, observational study. SUBJECTS: A total of 617 consecutive cases (516 males, mean age: 57.2+/-10.8 y) with CAD who underwent their first coronary angiography between January 2000 and May 2000. MEASUREMENTS: Before coronary angiography, their heights, weights, waist and hip circumferences were measured. Waist circumferences, BMI and WHRs were compared both as a whole and also within stratified groups as for sexes and age groups categorized in decades above 40 y of age. RESULTS: Overweight cases comprised approximately half of the patients in both sexes. In males, the percentages of obese cases with respect to BMIs were 15%, while males with action level 2 waist circumferences were detected to be 20%. Obese male patients whose WHRs were >or=0.95 were found to be 51%. In female cases, corresponding percentages of obesity were estimated to be 32, 72 and 86%, respectively. CONCLUSION: In the same patient groups, the prevalence of obesity, defined by BMI, waist circumference and WHR, could vary three-fold. Thus, some patients may not display a diagnosis of obesity. To prevent this possibility the waist circumference is an easy method, which reflects central obesity more accurately.

Angiographic findings of the multicenter Randomized Study With the Sirolimus-Eluting Bx Velocity Balloon-Expandable Stent (RAVEL): sirolimus-eluting stents inhibit restenosis irrespective of the vessel size.

BACKGROUND: Restenosis remains the major limitation of coronary catheter-based intervention. In small vessels, the amount of neointimal tissue is disproportionately greater than the vessel caliber, resulting in higher restenosis rates. In the Randomized Study With the Sirolimus-Eluting Bx Velocity Balloon-Expandable Stent (RAVEL) trial, approximately 40% of the vessels were small (<2.5 mm). The present study evaluates the relationship between angiographic outcome and vessel diameter for sirolimus-eluting stents. METHODS AND RESULTS: Patients were randomized to receive either an 18-mm bare metal Bx VELOCITY (BS group, n=118), or a sirolimus-eluting Bx VELOCITY stent (SES group, n=120). Subgroups were stratified into tertiles according to their reference diameter (RD; stratum I, RD <2.36 mm; stratum II, RD 2.36 mm to 2.84 mm; stratum III, RD >2.84 mm). At 6-month follow-up, the restenosis rate in the SES group was 0% in all strata (versus 35%, 26%, and 20%, respectively, in the BS group). In-stent late loss was 0.01+/-0.25 versus 0.80+/-0.43 mm in stratum I, 0.01+/-0.38 versus 0.88+/-0.57 mm in stratum II, and -0.06+/-0.35 versus 0.74+/-0.57 mm in stratum III (SES versus BS). In SES, the minimal lumen diameter (MLD) remained unchanged (Delta -0.72 to 0.72 mm) in 97% of the lesions and increased (=late gain, DeltaMLD <-0.72 mm) in 3% of the lesions. Multivariate predictors for late loss were treatment allocation (P<0.001) and postprocedural MLD (P= 0.008). CONCLUSIONS: Sirolimus-eluting stents prevent neointimal proliferation and late lumen loss irrespective of the vessel diameter. The classic inverse relationship between vessel diameter and restenosis rate was seen in the bare stent group but not in the sirolimus-eluting stent group.

Sirolimus eluting stent in the treatment of atherosclerosis coronary artery disease.

Stent implantation represents the most commonly performed percutaneous coronary intervention nowadays. However, instent restenosis due to exaggerated neointimal hyperplasia remains a problem to overcome. Neointimal hyperplasia is a vascular response to stent injury; it mainly consists of smooth muscle cells proliferation. The underlying molecular mechanisms of restenosis were explained in this review article. Recently, drug-eluting stent has been proposed as a potential method to prevent instent restenosis. Animal studies have confirmed safety and efficacy of sirolimus-eluting stent implantation in vivo. The FIM trial, which was the first clinical study on sirolimus-eluting stent in de novo lesions, has shown an astonishing 0% restenosis rate. The RAVEL trial was the first prospective, double-blind, multi-center trial that randomized 238 patients at 19 institutions with de novo lesions into sirolimus-eluting versus bare Bx velocity stent. Six-month binary restenosis rate in the sirolimus-group was again 0% compared to 26.6% in the control group. Angiographic late loss and major cardiac event were also significantly lower in the sirolimus-group. The SIRIUS trial is an ongoing study conducted in 53 US centers that randomized 1100 patients with de novo lesion into sirolimus-eluting and bare stents. Preliminary results also showed a significant reduction in binary restenosis, late loss and repeat revascularization rates. Apart from de novo lesions, early experience of sirolimus-eluting stent implantation for instent restenosis in non-randomized study was also promising, achieving a single-digit repeat restenosis rate. As compare with standard coronary stent, a sirolimus-eluting stent shows considerable promise for the prevention of neointimal proliferation, restenosis and associated clinical events.

Cardiac thrombosis in a patient with Behçet's disease: two years follow-up.

A 28-year-old man with Behçet's disease was presented with cardiac symptoms in addition to previous complaints of oral and genital ulcers. A diagnosis of thrombosis was made and patient began to receive anticoagulant and immunosuppressive therapy and was followed by echocardiographic examination. Despite medical therapy, thrombosis recurred. Surgical excision was performed and histological findings were consistent with organizing thrombus. Nature of cardiac involvement and review of literature on cardiac thrombosis in Behçet's disease was discussed.

Exercise electrocardiography test in patients with aortic stenosis. Differential features from that of coronary artery disease.

BACKGROUND AND AIM OF THE STUDY: Studies that have been conducted with an exercise test in patients with aortic stenosis (AS) have demonstrated that results of an exercise test can mimic that of coronary artery disease (CAD). The objective of our study was to investigate if there was any differential feature(s) of an exercise test in patients with AS compared to those with CAD. METHODS: We prospectively studied 42 patients with AS (AS group, age 37 +/- 23, range 8-75) with an averaged maximal gradient of 42 +/- 19 mmHg (range 26-95). All patients had undergone a coronary angiography within 1 week of the exercise test and none had CAD. Another 100 patients with CAD, diagnosis proven with coronary angiography, comprised our second group for the comparison (CAD group). Cornell protocol was used in all patients. RESULTS: ST-segment depression was observed in all patients (160 +/- 25 microV in AS group and 170 +/- 20 microV in CAD group, P>0.05). Thirty-four (81%) patients in AS group and 88 (88%) patients in CAD group exceeded the classical threshold for the test positivity (P>0.05). ST/HR slopes derived from heart rate adjustment to ST-segment level did not differ between the study groups (3.2 +/- 2.3 and 3.7 +/- 2.2 microV/beat/min, in AS and CAD groups, respectively, P>0.05). Recovery-phase patterns of ST-segment in heart rate domain were quite different between AS and CAD (clockwise loop: 86% vs. 0%; counterclockwise loop: 9% vs. 88% in AS group and CAD group, respectively, both P<0.0001). Percentage of intermediate loop was 5% in AS group and 12% in CAD group (P>0.05). CONCLUSIONS: Our study demonstrated that patients with AS could be distinguished from those with CAD with the method of rate-recovery loop analysis.

Microbubbles associated with mechanical heart valves: their relationwith serum lactic dehydrogenase levels.

BACKGROUND: There has been no consensus about the prevalence and mechanism of generation of microbubbles in mechanical prosthetic heart valves (PHV). The aim of this study was to determine the prevalence of microbubbles in PHV and their relation to serum lactic dehydrogenase (LDH) levels. METHODS AND RESULTS: We prospectively studied 150 normally functioning mitral PHV (98 bileaflet and 52 monoleaflet) in 150 patients with the use of transesophageal echocardiography with a multiplane 5-MHz probe. None of the patients had an aortic prosthetic valve. Blood was drawn to determine serum LDH level. None of the patients had any factors that might affect the LDH level other than the PHV-related hemolysis. Patients with spontaneous echo contrast in the left atrium that might affect the assessment of the microbubbles were excluded. We devised a method to determine the amount of microbubbles for each PHV. Microbubbles were detected in 118 (79%) of 150 PHV, including 97 (99%) of 98 bileaflet valves and 21 (40%) of 52 monoleaflet (tilting disk) valves (P <. 0001). Intraobserver variability was not statistically significant for the determination of the amount of microbubbles (z = 1.7, P =. 08). There was a strong correlation between serum LDH levels and the amount of microbubbles (rs = 0.69, P <.001). CONCLUSIONS: Microbubbles were detected in more patients than reported previously. They were found to be associated more with the bileaflet than the monoleaflet PHV. Sorin monoleaflet valves were associated with microbubbles significantly less often than the others. There was a strong correlation between serum LDH levels and microbubble counts, which suggests that hemolysis may be related to microbubble formation.

High prevalence of hypercoagulable states in patients with recurrent thrombosis of mechanical heart valves.

BACKGROUND AND AIMS OF THE STUDY: Thrombosis is one of the most feared and life-threatening complications of mechanical heart valves (MHV), with an incidence of 1-3 per 100 patient-years. Hypercoagulable states are highly prevalent in the general population and can predispose MHV to thrombus formation. Thus, we conducted a study to investigate the frequency of hypercoagulable states in patients with MHV who had recurrent thrombosis at least twice after valve implantation. METHODS: Fifteen patients (mean age 42 +/- 11 years; range: 18 to 55 years) with recurrent thrombosis of MHV (2.4 +/- 0.8 recurrences/patient) (group 1) and 15 matched patients (mean age 40 +/- 12 years; range: 18 to 55 years) with MHV without thrombosis (group 2) were followed up with transthoracic and transesophageal echocardiography. Patients' sera were monitored for antibodies to cardiolipin (ACLA-IgG and ACLA-IgM), phosphatidylserine (APSA), lupus-type anticoagulant (LA) and lipoprotein(a) (LP(a)). RESULTS: Average values for group 1 versus group 2 were: ACLA-IgG (normal range < 15 GPLU/ml) 24.7 +/- 14.6 versus 6.2 +/- 2.7 (p < 0.001); ACLA-IgM (< 12.5 MPLU/ml) 7.9 +/- 5.0 versus 3.3 +/- 1.7 (u = 185; p < 0.001); APSA (< 12 RLU/ml) 4.8 +/- 5.7 and 2.9 +/- 1.2 (p = 0.56); and LP(a) (< 30 mg/dl) 36.5 +/- 26.5 and 13.4 +/- 7.1 (p < 0.001). The frequency of LA-positive cases was 4/15 in group 1 and 0/15 in group 2 (p > 0.05). The frequency of abnormally high levels of ACLA-IgG was 9/15 in group 1 and 0/15 in group 2 (p < 0.001); of ACLA-IgM, 2/15 in group 1 and 0/15 in group 2 (p > 0.05); of APSA, 1/15 in group 1 and 0/15 in group 2 (p > 0.05); and of LP(a), 5/15 in group 1 and 0/15 in group 2 (p < 0.05). At least one of the factors included in this study was abnormal in 14 of 15 (93%) patients (p < 0.0001). CONCLUSIONS: Hypercoagulable states are highly prevalent in patients with recurrent thrombosis of MHV. All patients evaluated for therapy of obstructive thrombosis of MHV should be investigated for hypercoagulable state. Moreover, in high-risk patients, surgical replacement of the MHV with a bioprosthesis should be considered.

Contrast echoes detected during percutaneous mitral balloon commissurotomy with Inoue balloons and their relation to cerebral microembolic signals.

The aim of this study was to find out the mechanism of genesis of contrast echoes detected with echocardiography during percutaneous mitral balloon commissurotomy (PMBC) procedures with Inoue balloons and to assess their association with cerebral microembolic signals with transcranial Doppler examinations. Ten Inoue balloons (Toray Instruments) were used in 10 patients (mean age 36 +/- 10 years). In all patients transesophageal echocardiographies with a multiplane 5 MHz probe were performed immediately before and during the PMBC procedure. None of the patients had left atrial thrombus during the PMBC. All of the balloons were inflated within the left atriums and left ventricles and were tested in saline to see whether there was a visible air leak after the PMBC procedures. Transcranial Doppler examinations were done with 2 MHz probes from the middle cerebral artery. Contrast echoes were detected in all patients during inflation and/or deflation, independent of the intracardiac sites. After a few cardiac cycles there was a very intense shower of microembolic signals detected with the transcranial Doppler examination, which persisted for all inflations and/or deflations. All balloons yielded visible air leaks from the two small holes at the waist of the balloons in saline. There were a few contrast echoes recorded in some of the patients during the exchange of equipment, and one patient had a transient neurologic and coronary ischemic event following the introduction of the stretcher tube of the Inoue balloon. Intracardiac contrast echoes and transcranial microembolic signals during the PMBC procedure were detected in all PMBC procedures and were due to air that was entrapped between the two latex layers of the Inoue balloons and air introduced from outside during the exchange of the equipment.

Application of proximal isovelocity surface area method to determine prosthetic mitral valve area.

BACKGROUND: In this study, we investigated the accuracy of orifice area determination of the prosthetic valve (Biocor) by using proximal isovelocity surface area method (PISA). Thirty-two patients (26 women, 6 men; mean age 44 +/- 8.1 years) were studied. Eleven patients were in normal sinus rhythm and the rest were in atrial fibrillation. Associated valvular lesions were mild aortic regurgitation in 12 patients and moderate tricuspid regurgitation in 19 patients. Sizes of prosthetic valves were 27 to 31, and implantation duration was 4 to 8 years. METHODS AND RESULTS: We analyzed the flow convergence zone proximal to the valve orifice with the concept of a hemispheric model. Mitral valve area (MVA) calculation was formulated by MVA = 2pi r2 x Va/Vm x (Vm/Vm-Va), where Vm is the maximal mitral velocity and Vm/Vm - Va is a correction factor to account for flattening of isotachs near the prosthetic orifice. MVA calculations by PISA were compared with pressure half-time (PHT), continuity equation (CONT), and color flow area (CFA) methods. Mitral valve areas were 2.17 +/- 0.17 cm2, 2.22 +/- 0.21 cm2, 2.19 +/- 0.22 cm2, and 2.16 +/- 0.17 cm2 in PISA, CFA, PHT, and CONT methods, respectively. Values in the comparison of MVA measurements by different methods were PISA vs PHT, r =.86; PISA vs CFA, r =.77; and PISA vs CONT, r =.89. CONCLUSIONS: The PISA method gives reliable estimates of large orifices such as prosthetic valves. Although the best correlation was seen with the CONT method, results of this study also confirmed that the PISA method can be applied with reasonable accuracy.

Less invasive approaches for closed mitral commissurotomy.

OBJECTIVE: Recently, closed mitral commissurotomy (CMC) has been reexplored due to the concepts of less invasive valvular surgery. The feasibility of closed mitral commissurotomy via port access or limited thoracotomy by aid transesophageal echocardiography (TEE) was investigated in this clinical study. METHODS: Between August 1996 and April 1998, 42 patients (32 women, ten men with a mean age of 36.2+/-7.8 years) underwent less invasive CMC at the Kosuyolu Heart and Research Hospital. CMC procedure were done through a limited (12-16 cm) thoracotomy incision in 23 patients, a very limited or mini thoracotomy incision (7-8 cm) in 11 patients and port access by aid TEE in eight patients. Preoperative mean mitral valve area was calculated as 1.19+/-0.13 cm2 and mean mitral valve gradient was measured as 14.8+/-3.2 mmHg. TEE provided information about the mitral valve anatomy and functions during the procedure in all patients. RESULTS: Commissurotomy was successfully performed in all patients. In eight patients, a Tubbs dilator was inserted via port access at the 6th intercostal space from a 3-cm incision. Incision by guidance of TEE and CMC could be performed without thoracotomy in five patients. In three patients of the port access group, a very limited thoracotomy was required to perform CMC by digital guidance. Postoperative mean MVA was 2.37+/-0.29 cm2, minimal mitral gradient was 5.3+/-1.7 mmHg. In eleven patients, minimal mitral regurgitation was observed. The operations and postoperative period were free of complications in all patients. Following an average 12+/-2.8 h intensive care unit period, all patients were discharged after an average of 3.4+/-0.8 days of hospitalization. CONCLUSION: Limited thoracotomy has less detrimental structural effects in patients. Port access by aid TEE approach to CMC may offer less invasiveness, lower cost effectiveness and be an alternative to percutaneous balloon mitral valvotomy.

Prevalence of microbubbles associated with mechanical prosthetic cardiac valves: a prospective transesophageal echocardiography study.

BACKGROUND AND AIM OF THE STUDY: The study aim was to identify the prevalence of microbubbles in different types of mechanical cardiac valve and, if feasible, to associate microbubbles with various clinical conditions, including thrombotic occlusion of the valves. METHODS: A total of 153 mechanical prosthetic valves were studied (58 aortic, 95 mitral) in 140 patients, prospectively. All valves were functioning normally. In addition, eight mitral prosthetic valves were selected without microbubbles and with an obstructive valvular thrombosis that had undergone successful thrombolysis (group 1); a further eight patients with unsuccessful thrombolysis (group 2) were studied by transesophageal echocardiography before and after thrombolytic therapy. RESULTS: Microbubbles were detected in 75% (114/153) of prosthetic valves, 99% (88/89) of bileaflet valves, and 45% (29/64) of monoleaflet valves (p < 0.0001). Only 14% (4/28) of Sorin monoleaflet valves were associated with microbubbles, which is distinctively less than other valves (p < 0.001 for each); 71% and 77% of aortic and mitral prosthetic valves, respectively, were associated with microbubbles (p = NS). Prosthetic valves with an obstructive thrombosis and no microbubbles in group 1 showed new appearance of microbubbles in 88% (7/8) of cases after successful thrombolysis. Absence of microbubbles in group 2 persisted in all eight patients at the second examination. CONCLUSIONS: Microbubbles were detected in a greater proportion of patients than reported previously and were found to be associated more with bileaflet prosthetic heart valves than with monoleaflet valves. Sorin monoleaflet valves were associated with microbubbles dramatically less than all other valves. The new appearance of microbubbles after thrombolytic therapy of mechanical prosthetic heart valves with an obstructive thrombosis may indicate successful thrombolysis.